Edward Stuart
Administration
ImmunoQure AG
Germany
Biography
Ed started his industrial career as COO of DeveloGen AG before co-founding and becoming the Managing Director and CBO of U3 Pharma AG. Subsequently, Ed became the founding CEO of Neurimmune Therapeutics AG. He also acted as the founding CEO of CT Atlantic AG (Zurich, Switzerland), an oncology-focused spin-off from the University of Zurich and the Ludwig Institute for Cancer Research and is a co-founder of HS LifeSciences and QureInvest. He studied pharmacology in University College Dublin, Ireland, where he was awarded his Ph.D. and was a post-doctoral scientist at the Max Planck Institute in Gottingen followed by his appointment as a Lecturer in Medical Genetics in Imperial College London, UK. Ed also holds an MBA from The Business School of Imperial College London, UK.
Research Interest
Cancer Research
